Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
19.97
-2.55 (-11.32%)
At close: Apr 4, 2025, 4:00 PM
21.00
+1.03 (5.16%)
After-hours: Apr 4, 2025, 7:35 PM EDT
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,100,517
Profits / Employee
-$278,701
Market Cap
2.51B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APLS News
- 3 days ago - FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
- 3 days ago - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 4 weeks ago - Apellis Pharmaceuticals: A Mixed Bag - Seeking Alpha
- 4 weeks ago - Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
- 4 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire